Lisata Therapeutics, Inc.
LSTAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Lisata Therapeutics, Inc. (LSTA) is listed under Biotechnology. The company carries a $10.8M market cap, placing it firmly in the micro-cap category. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Market Cap
$10.8M
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-0.86
EPS (TTM)
$-1.62
EPS (Fwd)
$-1.16
ROE
-101.7%
ROA
-56.7%
Cash
$10.4M
Total Debt
$0
Free CF
-$8.1M
52W Change
-57.5%
Annual Financials
Cash vs Debt
Where LSTA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LSTA finished 63.50% below its 150-day moving average ($2.74) and 67.11% below its 200-day moving average ($3.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LSTA overbought or oversold?
At the October 20, 2026 close, LSTA's RSI(14) was 20.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lisata Therapeutics, Inc. reports $10.4M in cash and $0 in total debt. Free cash flow is running at -$8.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -101.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LSTA.